Fosaprepitant Dimeglumine + 5-HT3 antagonist + Dexamethasone
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Chemotherapy-induced Nausea and Vomiting
Conditions
Chemotherapy-induced Nausea and Vomiting
Trial Timeline
Sep 9, 2019 → Feb 11, 2021
NCT ID
NCT04054193About Fosaprepitant Dimeglumine + 5-HT3 antagonist + Dexamethasone
Fosaprepitant Dimeglumine + 5-HT3 antagonist + Dexamethasone is a approved stage product being developed by Merck for Chemotherapy-induced Nausea and Vomiting. The current trial status is completed. This product is registered under clinical trial identifier NCT04054193. Target conditions include Chemotherapy-induced Nausea and Vomiting.
What happened to similar drugs?
2 of 20 similar drugs in Chemotherapy-induced Nausea and Vomiting were approved
Approved (2) Terminated (4) Active (15)
🔄Hetrombopag Olamine + Hetrombopag Olamine ；Hetrombopag Olamine PlaceboJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04054193 | Approved | Completed |
Competing Products
20 competing products in Chemotherapy-induced Nausea and Vomiting